 Ten months since Optheas ASX:OPT drug proved itself against wet-AMD, its passed another clinical trial against Diabetic Macular Edema DME. This morning the company conducted a 144-patient phase 2a clinical trial against DME, which is a smaller market than wet-AMD, but is similar in that it results in vision loss from fluid leakage in the ... 